Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Original Article
T.D. Shanafelt, X.V. Wang, N.E. Kay, C.A. Hanson, S. O’Brien, J. Barrientos, D.F. Jelinek, E. Braggio, J.F. Leis, C.C. Zhang, S.E. Coutre, P.M. Barr, A.F. Cashen, A.R. Mato, A.K. Singh, M.P. Mullane, R.F. Little, H. Erba, R.M. Stone, M. Litzow, and M. Tallman
N Engl J Med 2019;381:432-443
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Sunday, August 1, 2021 - 11:59pm.